Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10919686 | Radiotherapy and Oncology | 2011 | 10 Pages |
Abstract
Overall, outcome after CHARTWEL or CF was not different. The lower total dose in the CHARTWEL arm was compensated by the shorter overall treatment time, confirming a time factor for NSCLC. The higher efficacy of CHARTWEL versus CF in advanced stages and after chemotherapy provides a basis for further trials on treatment intensification for locally advanced NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Baumann, T. Herrmann, R. Koch, W. Matthiessen, S. Appold, B. Wahlers, L. Kepka, G. Marschke, D. Feltl, R. Fietkau, V. Budach, J. Dunst, R. Dziadziuszko, M. Krause, D. Zips,